

06-25-2021

11:30 - 12:30	Industry satellite symposium 1 (TBC)	Channel 1
12:45 - 13:20	Welcome to ESMO Gynae 2021 and Keynote address Moderation: S. Banerjee ¹ , D. Lorusso ² , A.M. Poveda Velasco ³ , ¹ London/GB, ² Rome/IT, ³ Valencia/ES	Channel 1
12:45 - 12:50	Live welcome <u>S. Banerjee</u> ¹ , <u>D. Lorusso</u> ² , <u>A.M. Poveda Velasco</u> ³ , ¹ London/GB, ² Rome/IT, ³ Valencia/ES	
12:50 - 12:55	Introduction to the Keynote lecture <u>S. Banerjee</u> , London/GB	
12:55 - 13:20	Keynote lecture: DNA damage repair in ovarian cancer and PARP inhibitors resistance <u>A. Oza</u> , Toronto/CA	
13:35 - 14:50	Treatment of newly diagnosed ovarian cancer: Where are we in 2021 and what's next? Moderation: D.S. Tan ¹ , N. Concin ² , ¹ Singapore/SG, ² Innsbruck/AT	Channel 1
13:35 - 13:50	The evolving role of molecular profiling for therapeutic stratification in newly diagnosed ovarian cancer <u>D.S. Tan</u> , Singapore/SG	
13:50 - 14:05	The role of surgery for newly diagnosed ovarian cancer: Current status and future directions <u>S. Mahner</u> , Munich/DE	
14:05 - 14:20	First line maintenance therapy for ovarian cancer in 2021: What are the options? <u>I. Ray-Coquard</u> , Lyon/FR	
14:20 - 14:35	Horizon scanning: What's next for systemic therapy in ovarian cancer - first line and beyond? <u>D. Lorusso</u> , Rome/IT	
14:35 - 14:50	Live Q&A and discussion	

15:05 - 16:20	1st line maintenance strategy options for advanced ovarian cancer by HRD profile Moderation: A. Oza ¹ , D. Cibula ² , ¹ Toronto/CA, ² Prague/CZ	Channel 1
15:05 - 15:25	Clinical case - What options for HRD patients? Criteria for treatment choice <u>E. Kohn</u> , Bethesda/US	
15:25 - 15:45	Clinical case - What options for HR proficient patients? Criteria for treatment choice <u>N. Colombo</u> , Milan/IT	
15:45 - 16:05	Clinical case - Combination vs sequence: Clinical implications <u>S. Lheureux</u> , Toronto/CA	
16:05 - 16:20	Live Q&A and discussion	
16:35 - 17:35	Industry satellite symposium 2 (TBC)	Channel 1

06-26-2021

11:30 - 12:30 Industry satellite symposium 3 (TBC) Channel 1
12:45 - 14:15 Best of abstracts session Channel 1

12:45 - 14:15 **To be announced**

14:30 - 15:45 Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what's next? Channel 1
Moderation: A.M. Poveda Velasco, I. Romero, Valencia/ES

14:30 - 14:50 **Surgery in recurrent ovarian cancer: Patient selection and impact on 2nd line therapeutic strategies**
P. Harter, Essen/DE

14:50 - 15:10 **Do all patients with recurrent ovarian cancer need systemic therapy and which is the optimal treatment algorithm?**
M. Friedlander, Randwick/AU

15:10 - 15:30 **Current and emerging biomarkers in recurrent OvCa**
S. Banerjee, London/GB

15:30 - 15:45 **Live Q&A and discussion**

16:00 - 17:00 Immunotherapy in ovarian cancer: Is there a future in clinical practice? Channel 1
Moderation: R. Coleman¹, M.R. Mirza², ¹Houston/US, ²Copenhagen/DK

16:00 - 16:15 **Live introduction**

16:15 - 16:30 **Yes**
E. Pujade-Lauraine, Paris/FR

16:30 - 16:45 **No**
K. Moore, Oklahoma City/US

16:45 - 17:00 **Live Q&A and discussion**

17:15 - 17:25 Closing remarks

Channel 1

Moderation: S. Banerjee¹, D. Lorusso², A.M. Poveda Velasco³, ¹London/GB, ²Rome/IT,
³Valencia/ES